Table 1 Comparisons among non-invasive markers of fibrosis in non-alcoholic fatty liver disease
First authorMethodParameterSubjects includedAUC value*Notes
Schmilovitz-Weiss1613C-caffeine breath testNA260.79Availability and standardisation limit the use in clinical practice.
Yoneda17Transient elastographyNA970.90The intrinsic limitation of subcutaneous adipose tissue to perform the larger studies including obese subjects.
Guha18Enhanced Liver Fibrosis panelHyaluronic acid + procollagen-3 N-terminal peptide + tissue inhibitor of metalloproteinases-11920.93The main limitation is the use of uncommon laboratory variables
Guha18Simple panelAge + body mass index + diabetes/impaired fasting glucose + AST/ALT + platelet count + albumin1920.89Good diagnostic accuracy with variables easily obtained in clinical practice.
Angulo19NAFLD fibrosis scoreAge + body mass index + diabetes/impaired fasting glucose + AST/ALT ratio +platelet count+ albumin7330.84
Harrison14BARD scoreBody mass index +AST/ALT ratio + diabetes mellitus8270.81Share the benefits of the previous scores, but the simplicity to calculate it, is valuable. Developed in obese subjects.
Poynard15FibroTestBilirubin, GGT, α2-macroglobulin, apolipoprotein A1, and haptoglobin, corrected for age and gender2670.84Unfeasible in clinical practice due to limited access (property brand) preventing general use due to cost.
  • *Area under the curve to predict advanced fibrosis.

  • ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUC, area under the curve; GGT, gamma-glutamyl transferase; NA, not applicable.